Dr. Carlos G. Grijalva is a Professor in the Division of Pharmacoepidemiology, Departments of Health Policy and Biomedical Informatics at Vanderbilt University Medical Center. His research interests include the study of vaccine-preventable respiratory diseases, the evaluation of medications safety and effectiveness, and methodologies for comparative effectiveness research. His research is particularly focused on influenza, SARS-CoV-2 and pneumococcal infections, and the evaluation of the effectiveness of vaccination and other preventive programs.
He is currently Co-Principal Investigator for two large multicenter household-based case ascertained studies that examine the risk of influenza, SARS-CoV-2 and RSV transmission in households in the United States. He is also Co-Principal Investigator in a large prospective cohort study of adult essential workers in Middle Tennessee. Dr. Grijalva has published more than 330 peer-reviewed articles, and his current work is supported by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), among other sources.
Further information:
Professor Pekka Nuorti, pekka.nuorti [at] tuni.fi (pekka[dot]nuorti[at]tuni[dot]fi)